{"filing":{"accession_number":"0001724521-26-000047","cik":"0001724521","ticker":"RCUS","company_name":"Arcus Biosciences, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"rcus-20261020.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm"},"events":[{"id":36301,"run_id":33468,"accession_number":"0001724521-26-000047","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Arcus Biosciences disclosed clinical trial data from the ARC-20 platform study evaluating casdatifan in multiple treatment settings for renal cell carcinoma, including efficacy metrics (PFS, ORR, OS) and safety profiles across first-line, second-line, and late-line cohorts. This represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline progress and competitive positioning in oncology, though it does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types.","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40669,"accession_number":"0001724521-26-000047","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Arcus Biosciences disclosed clinical trial data from the ARC-20 platform study evaluating casdatifan in multiple treatment settings for renal cell carcinoma, including efficacy metrics (PFS, ORR, OS) and safety profiles across first-line, second-line, and late-line cohorts. This represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline progress and competitive positioning in oncology, though it does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:34:37.075027+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40669,"accession_number":"0001724521-26-000047","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Arcus Biosciences disclosed clinical trial data from the ARC-20 platform study evaluating casdatifan in multiple treatment settings for renal cell carcinoma, including efficacy metrics (PFS, ORR, OS) and safety profiles across first-line, second-line, and late-line cohorts. This represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline progress and competitive positioning in oncology, though it does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:34:37.075027+00:00","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-10-20"}]}